FDA adcomms slated to review data on long-term opioid use, overdoses
FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two completed post-marketing studies the agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.